Jon Holmlund

2.4k total citations
55 papers, 1.7k citations indexed

About

Jon Holmlund is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Jon Holmlund has authored 55 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 28 papers in Oncology and 15 papers in Molecular Biology. Recurrent topics in Jon Holmlund's work include Oral health in cancer treatment (11 papers), Head and Neck Cancer Studies (11 papers) and Lung Cancer Treatments and Mutations (8 papers). Jon Holmlund is often cited by papers focused on Oral health in cancer treatment (11 papers), Head and Neck Cancer Studies (11 papers) and Lung Cancer Treatments and Mutations (8 papers). Jon Holmlund collaborates with scholars based in United States, Canada and Russia. Jon Holmlund's co-authors include Richard S. Geary, Andrew Dorr, T. Jesse Kwoh, F. Andrew Dorr, John Nemunaitis, Brett P. Monia, Casey Cunningham, Mario Sznol, Lance Leopold and Brian Wood and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Jon Holmlund

53 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jon Holmlund United States	24	1.1k	537	290	199	184	55	1.7k
Dagmar Hess Switzerland	20	880 0.8×	897 1.7×	368 1.3×	243 1.2×	267 1.5×	61	1.7k
Scott A. Boerner United States	23	1.2k 1.1×	852 1.6×	337 1.2×	238 1.2×	334 1.8×	40	2.2k
Edward M. Newman United States	26	1.1k 1.0×	1.2k 2.2×	431 1.5×	165 0.8×	199 1.1×	88	2.4k
Howard Fingert United States	23	765 0.7×	1.1k 2.0×	220 0.8×	100 0.5×	209 1.1×	47	1.9k
Maria Luisa Veronese United States	18	969 0.9×	678 1.3×	340 1.2×	107 0.5×	190 1.0×	35	1.8k
Yoshiyasu Nakamura Japan	25	650 0.6×	528 1.0×	398 1.4×	160 0.8×	325 1.8×	71	1.6k
Arnaldo Arbini United States	25	905 0.8×	433 0.8×	248 0.9×	161 0.8×	396 2.2×	55	1.9k
Kenneth Kolinsky United States	19	1.3k 1.2×	1.3k 2.3×	350 1.2×	326 1.6×	294 1.6×	33	2.3k
Christopher A. Slapak United States	23	1.1k 1.1×	1.3k 2.4×	247 0.9×	194 1.0×	251 1.4×	42	2.3k
Jeff Sosman United States	20	1.2k 1.1×	1.2k 2.2×	301 1.0×	498 2.5×	278 1.5×	38	2.2k

Countries citing papers authored by Jon Holmlund

Since Specialization

Citations

This map shows the geographic impact of Jon Holmlund's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Holmlund with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Holmlund more than expected).

Fields of papers citing papers by Jon Holmlund

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Holmlund. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Holmlund. The network helps show where Jon Holmlund may publish in the future.

Co-authorship network of co-authors of Jon Holmlund

This figure shows the co-authorship network connecting the top 25 collaborators of Jon Holmlund. A scholar is included among the top collaborators of Jon Holmlund based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jon Holmlund. Jon Holmlund is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Anderson, Carryn M., Christopher M. Lee, Gary V. Walker, et al.. (2022). ROMAN: Phase 3 trial of avasopasem manganese (GC4419) for severe oral mucositis (SOM) in patients receiving chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck cancer (LAHNC).. Journal of Clinical Oncology. 40(16_suppl). 6005–6005. 9 indexed citations

Hoffe, Sarah E., Jessica M. Frakes, Todd A. Aguilera, et al.. (2020). Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC). International Journal of Radiation Oncology*Biology*Physics. 108(5). 1399–1400. 12 indexed citations

Moser, Elizabeth Charlotte, Sarah E. Hoffe, Jessica M. Frakes, et al.. (2020). Adaptive dose optimization trial of stereotactic body radiation therapy (SBRT) with or without GC4419 (avasopasem manganese) in pancreatic cancer.. Journal of Clinical Oncology. 38(15_suppl). TPS4670–TPS4670.

Anderson, Carryn M., Stephen T. Sonis, Christopher M. Lee, et al.. (2017). Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 100(2). 427–435. 64 indexed citations

Ready, Neal, Nina Karaseva, С. В. Орлов, et al.. (2011). Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(4). 781–785. 74 indexed citations

Sonpavde, Guru, В. Б. Матвеев, John M. Burke, et al.. (2011). Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Annals of Oncology. 23(7). 1803–1808. 118 indexed citations

Grossman, Stuart A., Jane Β. Alavi, Jeffrey G. Supko, et al.. (2005). Efficacy and toxicity of the antisense oligonucleotide aprinocarsendirected against protein kinase C-α delivered as a 21-day continuousintravenous infusion in patients with recurrent high-grade astrocytomas. Neuro-Oncology. 7(1). 32–40. 44 indexed citations

Advani, Ranjana H., Bert L. Lum, George A. Fisher, et al.. (2005). A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Investigational New Drugs. 23(5). 467–477. 32 indexed citations

Rao, Sheela, David Watkins, David Cunningham, et al.. (2004). Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma. Annals of Oncology. 15(9). 1413–1418. 37 indexed citations

10.

Marshall, John L., Michael D. Johnson, John Hanfelt, et al.. (2004). A Phase II Trial of ISIS 3521 in Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 4(4). 268–274. 28 indexed citations

11.

Advani, Ranjana H., Prema P. Peethambaram, Bert L. Lum, et al.. (2004). A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21‐day infusion to patients with advanced ovarian carcinoma. Cancer. 100(2). 321–326. 56 indexed citations

12.

Holmlund, Jon. (2003). Applying Antisense Technology. Annals of the New York Academy of Sciences. 1002(1). 244–251. 36 indexed citations

13.

Oza, Amit M., Laurie Elit, K. Swenerton, et al.. (2003). Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)☆. Gynecologic Oncology. 89(1). 129–133. 55 indexed citations

14.

Monia, Brett P., Jon Holmlund, & F. Andrew Dorr. (2000). Antisense Approaches for the Treatment of Cancer. Cancer Investigation. 18(7). 635–650. 30 indexed citations

15.

Dean, Nicholas M., Robert A. McKay, & Jon Holmlund. (1998). Antisense Oligonucleotides as Inhibitors of Genes That Regulate AP-1: Pharmacology and Clinical Development. Antisense and Nucleic Acid Drug Development. 8(2). 147–151. 6 indexed citations

16.

Curti, Brendan D., Augusto C. Ochoa, Walter J. Urba, et al.. (1996). Influence of Interleukin-2 Regimens on Circulating Populations of Lymphocytes After Adoptive Transfer of Anti-CD3-Stimulated T Cells. Journal of Immunotherapy. 19(4). 296–308. 17 indexed citations

17.

Janik, John E., L.L. Miller, Daniele Longo, et al.. (1996). Phase II Trial of Interleukin 1 and Indomethacin in Treatment of Metastatic Melanoma. JNCI Journal of the National Cancer Institute. 88(1). 44–49. 22 indexed citations

18.

Gause, Barry L., Mario Sznol, William C. Kopp, et al.. (1996). Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.. Journal of Clinical Oncology. 14(8). 2234–2241. 24 indexed citations

19.

Smith, John W., W. Gregory Alvord, John E. Janik, et al.. (1993). The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin. New England Journal of Medicine. 328(11). 756–761. 98 indexed citations

20.

Curti, Brendan D., Daniele Longo, Augusto C. Ochoa, et al.. (1993). Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2.. Journal of Clinical Oncology. 11(4). 652–660. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact